Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Epigenetic dysregulation in cancer.

Literature DB >> 19717641

Epigenetic dysregulation in cancer.

Abstract

One of the great paradoxes in cellular differentiation is how cells with identical DNA sequences differentiate into so many different cell types. The mechanisms underlying this process involve epigenetic regulation mediated by alterations in DNA methylation, histone posttranslational modifications, and nucleosome remodeling. It is becoming increasingly clear that disruption of the "epigenome" as a result of alterations in epigenetic regulators is a fundamental mechanism in cancer. This has major implications for the future of both molecular diagnostics as well as cancer chemotherapy.

Entities: Disease

Mesh：

Year: 2009 PMID： 19717641 PMCID： PMC2751531 DOI： 10.2353/ajpath.2009.081142

Source DB: PubMed Journal: Am J Pathol ISSN： 0002-9440 Impact factor: 4.307

99 in total

1. Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications.

Authors: Thomas A Milne; Mary Ellen Martin; Hugh W Brock; Robert K Slany; Jay L Hess
Journal: Cancer Res Date: 2005-12-15 Impact factor: 12.701

Review 2. Epigenetic therapy of cancer: past, present and future.

Authors: Christine B Yoo; Peter A Jones
Journal: Nat Rev Drug Discov Date: 2006-01 Impact factor: 84.694

3. The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion.

Authors: Leonie M Kamminga; Leonid V Bystrykh; Aletta de Boer; Sita Houwer; José Douma; Ellen Weersing; Bert Dontje; Gerald de Haan
Journal: Blood Date: 2005-11-17 Impact factor: 22.113

4. The polycomb group protein enhancer of zeste homolog 2 (EZH 2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype.

Authors: Paula A Croonquist; Brian Van Ness
Journal: Oncogene Date: 2005-09-15 Impact factor: 9.867

5. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast.

Authors: Ingeborg M Bachmann; Ole J Halvorsen; Karin Collett; Ingunn M Stefansson; Oddbjørn Straume; Svein A Haukaas; Helga B Salvesen; Arie P Otte; Lars A Akslen
Journal: J Clin Oncol Date: 2005-12-05 Impact factor: 44.544

Review 6. The fellowships of the INGs.

Authors: Xiaobing Shi; Or Gozani
Journal: J Cell Biochem Date: 2005-12-15 Impact factor: 4.429

7. The Polycomb group protein EZH2 directly controls DNA methylation.

Authors: Emmanuelle Viré; Carmen Brenner; Rachel Deplus; Loïc Blanchon; Mario Fraga; Céline Didelot; Lluis Morey; Aleyde Van Eynde; David Bernard; Jean-Marie Vanderwinden; Mathieu Bollen; Manel Esteller; Luciano Di Croce; Yvan de Launoit; François Fuks
Journal: Nature Date: 2005-12-14 Impact factor: 49.962

8. Comprehensive genomic analysis of desmoplastic medulloblastomas: identification of novel amplified genes and separate evaluation of the different histological components.

Authors: A Ehrbrecht; U Müller; M Wolter; A Hoischen; A Koch; B Radlwimmer; B Actor; A Mincheva; T Pietsch; P Lichter; G Reifenberger; R G Weber
Journal: J Pathol Date: 2006-03 Impact factor: 7.996

9. ING tumor suppressor proteins are critical regulators of chromatin acetylation required for genome expression and perpetuation.

Authors: Yannick Doyon; Christelle Cayrou; Mukta Ullah; Anne-Julie Landry; Valérie Côté; William Selleck; William S Lane; Song Tan; Xiang-Jiao Yang; Jacques Côté
Journal: Mol Cell Date: 2006-01-06 Impact factor: 17.970

Review 10. The SET-domain protein superfamily: protein lysine methyltransferases.

Authors: Shane C Dillon; Xing Zhang; Raymond C Trievel; Xiaodong Cheng
Journal: Genome Biol Date: 2005-08-02 Impact factor: 13.583

21 in total

Review 1. Dysregulation of BCL-2 family proteins by leukemia fusion genes.

Authors: Lauren M Brown; Diane T Hanna; Seong L Khaw; Paul G Ekert
Journal: J Biol Chem Date: 2017-07-17 Impact factor: 5.157

2. Chromatin status of apoptosis genes correlates with sensitivity to chemo-, immune- and radiation therapy in colorectal cancer cell lines.

Authors: Anne Benard; Connie M Janssen; Peter J van den Elsen; Marja C J A van Eggermond; Dave S B Hoon; Cornelis J H van de Velde; Peter J K Kuppen
Journal: Apoptosis Date: 2014-12 Impact factor: 4.677

3. [DNA methylation. From basic research to routine diagnostics].

Authors: U Lehmann
Journal: Pathologe Date: 2010-10 Impact factor: 1.011

4. Epigenetic modulation and apoptotic induction by a novel imidazo-benzamide derivative in human lung adenocarcinoma cells.

Authors: Amrutha Arjunan; Sankar Pajaniradje; Arul Prakash Francis; Srividya Subramanian; Sathyapriya Chandramohan; D Parthasarathi; Ayyiliath M Sajith; M Syed Ali Padusha; P P Mathur; Rukkumani Rajagopalan
Journal: Daru Date: 2021-10-12 Impact factor: 4.088

5. H3K4 demethylase KDM5B regulates cancer cell identity and epigenetic plasticity.

Authors: Runsheng He; Besa Xhabija; Lijin K Gopi; Jiji T Kurup; Zhishan Xu; Zhe Liu; Benjamin L Kidder
Journal: Oncogene Date: 2022-04-19 Impact factor: 8.756

Review 6. Epigenetic therapy in gastrointestinal cancer: the right combination.

Authors: Eihab Abdelfatah; Zachary Kerner; Nainika Nanda; Nita Ahuja
Journal: Therap Adv Gastroenterol Date: 2016-05-01 Impact factor: 4.409

7. Human cancer classification: a systems biology- based model integrating morphology, cancer stem cells, proteomics, and genomics.

Authors: Halliday A Idikio
Journal: J Cancer Date: 2011-02-22 Impact factor: 4.207